Egrifta SV
Egrifta SV Uses, Dosage, Side Effects, Food Interaction and all others data.
Egrifta SV is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Egrifta SV stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels.
| Trade Name | Egrifta SV |
| Availability | Prescription only |
| Generic | Tesamorelin |
| Tesamorelin Other Names | GHRH(1-44), Tesamorelin |
| Related Drugs | Egrifta, metreleptin, Myalept |
| Weight | 1mg, 2mg |
| Type | Kit, Subcutaneous Powder For Injection |
| Formula | C216H360N72O63S |
| Weight | Average: 5005.76 Monoisotopic: 5002.690032114 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Egrifta SV is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
Egrifta SV acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Egrifta SV is also used to associated treatment for these conditions: Lipodystrophies
How Egrifta SV works
By acting on the pituitary cells in the brain, tesamorelin stimulates production and release of the endogenous hormone (hGRF). Egrifta SV therapy predisposes the patient to glucose intolerance and can also increase the risk of type 2 diabetes, so the drug is contraindicated in pregnancy.
Toxicity
Diarrhea, congestive heart failure, peripheral neuropathy, and loss of mobility were the four serious adverse events reported during the clinical studies
Food Interaction
No interactions found.Egrifta SV Drug Interaction
Unknown: aripiprazole, lorazepam, diphenhydramine, tadalafil, clomiphene, ubiquinone, rosuvastatin, duloxetine, omega-3 polyunsaturated fatty acids, simethicone, chorionic gonadotropin , dextromethorphan / guaifenesin, omega-3 polyunsaturated fatty acids, bifidobacterium infantis / lactobacillus acidophilus, pantoprazole, quetiapine, acetaminophen, sildenafil, acetaminophen / dextromethorphan / doxylamine, cholecalciferol
Egrifta SV Disease Interaction
Volume of Distribution
9.4±3.1 L/kg in healthy subjects. 10.5±6.1 L/kg in HIV-infected patients.
Elimination Route
The absolute bioavailability was determined to be less than 4% in healthy adult subjects following a 2 mg subcutaneous dose.
Half Life
26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.
Innovators Monograph
You find simplified version here Egrifta SV
